Press release
Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys
Royalty Pharma to provide tailored funding solution to enable MorphoSys’ acquisition of Constellation PharmaceuticalsInvestment is anchored by royalties on
About this update from Royalty Pharma Plc
[{"type":"text","content":"Royalty Pharma to provide tailored funding solution to enable MorphoSys’ acquisition of Constellation PharmaceuticalsInvestment is anchored by royalties on Janssen’s TremfyaPartnership also includes royalties on four development-stage therapies, Development Funding Bonds and an investment in MorphoSys common stockRoyalty Pharma to host conference call today, Wednesday, June 2 at 8:45am EDT NEW YORK and PLANEGG, Germany, June 02, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and MorphoSys AG (FSE: MOR; Nasdaq: MOR) today announced a $2.025 billion strategic funding partnership as part of MorphoSys’ $1.7 billion acquisition of Constellation Pharmaceuticals (Nasdaq: CNST). This partnership is expected to fuel the expansion of the combined company’s capabilities to help enable the development and potential approvals of important cancer treatments. This funding partnership is anchored by Royalty Pharma’s acquisition of MorphoSys’ rights to receive future royalties on Janssen’s Tremfya (guselkumab). Tremfya is an anti interleukin (IL)-23, approved for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis and is also in clinical development for ulcerative colitis and Crohn’s disease. In 2020, Tremfya generated sales of $1.347 billion. Royalty Pharma will also acquire the rights to receive royalties and certain milestone payments on four attractive development-stage therapies: Gantenerumab, an anti-amyloid-beta monoclonal antibody, in Phase 3 development for Alzheimer’s disease by Roche. Royalty Pharma will purchase the rights to receive 60% of MorphoSys’ future royalties on gantenerumab.Otilimab, a fully human monoclonal antibody that inhibits granulocyte-macrophage colony-stimulating factor (GMCSF), in Phase 3 development for rheumatoid arthritis by GlaxoSmithKline. Royalty Pharma will purchase the rights to receive 80% of MorphoSys’ future royalties and 100% of its future milestones on otilimab.Pelabresib, a bromodomain and extra-terminal (BET) inhibitor for myelofibrosis, in Phase 3 development by Constellation. Royalty Pharma will purchase the rights to receive 3% of future net sales of pelabresib.CPI-0209, a second-generation enhancer of zeste homolog 2 (EZH2) inhibitor, in Phase 2 development for hematological malignancies and solid tumors by Constella...